OBJECTIVE: To assess the potential effectiveness and costs of 4 commonly used strategies to manage abnormal early pregnancies (AEPs). STUDY DESIGN: A decision analysis model was constructed to compare 4 strategies to manage AEPs: (1) observation, (2) medical management, (3) manual vacuum aspiration (MVA), and (4) dilation and curettage (D&C). RESULTS: MVA was the most cost-effective strategy, at dollar 793 per cure, for a total cost of dollar 377 million per 500,000 women and a cure rate of 95%. D&C was more effective than MVA, with a cure rate of 99%, but was more expensive (dollar 2,333 per cure, for a total cost of dollar 1.2 billion). D&C cured 20,000 more patients than MVA; however, at a substantial cost of dollar 38,925 per additional cure. With other estimates at baseline, MVA remained more cost-effective than D&C until the efficacy of MVA was < 82% or the cost of D&C was < dollar 240. CONCLUSION: MVA is the most cost-effective strategy for managing AEP and would be appropriate in settings in which resources are limited. D&C remains a reasonable strategy; however, one must spend dollar 38,925 per additional cure. In the United States, MVA would save dollar 779 million per year relative to D&C.
OBJECTIVE: To assess the potential effectiveness and costs of 4 commonly used strategies to manage abnormal early pregnancies (AEPs). STUDY DESIGN: A decision analysis model was constructed to compare 4 strategies to manage AEPs: (1) observation, (2) medical management, (3) manual vacuum aspiration (MVA), and (4) dilation and curettage (D&C). RESULTS: MVA was the most cost-effective strategy, at dollar 793 per cure, for a total cost of dollar 377 million per 500,000 women and a cure rate of 95%. D&C was more effective than MVA, with a cure rate of 99%, but was more expensive (dollar 2,333 per cure, for a total cost of dollar 1.2 billion). D&C cured 20,000 more patients than MVA; however, at a substantial cost of dollar 38,925 per additional cure. With other estimates at baseline, MVA remained more cost-effective than D&C until the efficacy of MVA was < 82% or the cost of D&C was < dollar 240. CONCLUSION: MVA is the most cost-effective strategy for managing AEP and would be appropriate in settings in which resources are limited. D&C remains a reasonable strategy; however, one must spend dollar 38,925 per additional cure. In the United States, MVA would save dollar 779 million per year relative to D&C.
Authors: Lauren B Messinger; Connie E Alford; John M Csokmay; Melinda B Henne; Sunni L Mumford; James H Segars; Alicia Y Armstrong Journal: Fertil Steril Date: 2015-05-23 Impact factor: 7.329
Authors: Eden R Cardozo; Andrew D Clark; Nicole K Banks; Melinda B Henne; Barbara J Stegmann; James H Segars Journal: Am J Obstet Gynecol Date: 2011-12-11 Impact factor: 8.661
Authors: Mary Rausch; Scott Lorch; Karine Chung; Margaret Frederick; Jun Zhang; Kurt Barnhart Journal: Fertil Steril Date: 2011-12-21 Impact factor: 7.329
Authors: Vanessa K Dalton; Lisa H Harris; Sarah J Clark; Lisa Cohn; Ken Guire; A Mark Fendrick Journal: J Womens Health (Larchmt) Date: 2009-06 Impact factor: 2.681
Authors: Oliver Zivanovic; Kaled M Alektiar; Yukio Sonoda; Qin Zhou; Alexia Iasonos; William P Tew; John P Diaz; Dennis S Chi; Richard R Barakat; Nadeem R Abu-Rustum Journal: Gynecol Oncol Date: 2008-09-06 Impact factor: 5.482
Authors: Blair G Darney; Marcia R Weaver; Deborah VanDerhei; Nancy G Stevens; Sarah W Prager Journal: BMC Health Serv Res Date: 2013-04-03 Impact factor: 2.655